{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)","item":"https:\/\/www.regionalcancercare.org\/trials\/an-adaptive-phase-3-randomized-open-label-multicenter-study-to-compare-the-efficacy-and-safety-of-axicabtagene-ciloleucel-versus-standard-of-care-therapy-as-first-line-therapy-in-subjects-with-high\/#breadcrumbitem"}]}